Exagen Management
Management criteria checks 1/4
Exagen’s CEO is John Aballi, appointed in Oct 2022, he has a tenure of less than a year. His total yearly compensation is US$1.4m, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. He directly owns 0.5% of the company’s shares, worth US$240.4k. The average tenure of the management team and the board of directors is less than a year and 3.4yrs respectively.
Key information
John Aballi
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 7.9% |
| CEO tenure | less than a year |
| CEO ownership | 0.5% |
| Management average tenure | less than a year |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Comp. | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | US$1m | US$111k | -US$47m |
Compensation vs Market: John's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD402.55K).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
CEO
John Aballi (37 yo)
less than a year
Tenure
US$1,409,342
Compensation
Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022. Most recently he served as SVP, General Manager, Urology & CLIA COO at Veracyte Inc. Mr. Aba...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of Board | 3.8yrs | US$89.68k | 0% $ 0 | |
| CEO, President & Director | less than a year | US$1.41m | 0.53% $ 240.4k | |
| CFO & Corporate Secretary | 5.9yrs | US$1.04m | 0.28% $ 125.3k | |
| Chief Business Officer | 1.3yrs | US$1.04m | 1.13% $ 508.0k | |
| Investors Relations Officer | no data | no data | no data | |
| Senior Vice President of Sales and Marketing | 9.5yrs | no data | no data | |
| Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | less than a year | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
0.6yrs
Average Tenure
50.5yo
Average Age
Experienced Management: E08A's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of Board | 3.8yrs | US$89.68k | 0% $ 0 | |
| CEO, President & Director | less than a year | US$1.41m | 0.53% $ 240.4k | |
| Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Breast Cancer Advisory Board | no data | no data | no data | |
| Member of Breast Cancer Advisory Board | no data | no data | no data | |
| Independent Director | 3.8yrs | US$33.75k | 0% $ 0 | |
| Member of Breast Cancer Advisory Board | no data | no data | no data | |
| Independent Director | 14.8yrs | US$103.68k | 0% $ 0 | |
| Member of Breast Cancer Advisory Board | no data | no data | no data | |
| Member of Breast Cancer Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | 3.4yrs | US$130.00k | no data | |
| Additional Independent Director | 1.9yrs | US$86.68k | 0% $ 0 |
3.4yrs
Average Tenure
63yo
Average Age
Experienced Board: E08A's board of directors are considered experienced (3.4 years average tenure).